Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1132 results about "Natural Killer Cell Inhibitory Receptors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Natural killer cell activation is determined by the balance of inhibitory and activating receptor stimulation. For example, if the inhibitory receptor signaling is more prominent, then NK cell activity will be inhibited; similarly, if the activating signal is dominant, then NK cell activation will result.
Generation and application of universal T cells for B-ALL
InactiveUS20070036773A1Hinder recognitionEnhanced siRNA effectBiocideGenetic material ingredientsAntigenNatural Killer Cell Inhibitory Receptors
The present invention is directed to universal T cells and their use in treating diseases and other physiological conditions. More specifically, the present invention is directed to universal T cells and their use in treating treating B-lineage acute lymphoblastic leukemia (B-ALL) in particular and malignancy in general. The universal T cells contain (i) nucleic acid encoding a chimeric antigen receptor (CAR) to redirect their antigen specificity and effector function and (ii) nucleic acids encoding shRNA and / or siRNA molecules to down-regulate cell-surface expression of T cell classical HLA class I and / or II genes to avoid recognition by recipient T cells. The universal T cells may also contain a nucleic acid encoding a non-classical HLA gene, such as an HLA E gene to enforce expression of HLA E genes and / or an HLA G gene to enforce expression of HLA G genes, to avoid recognition by recipient NK cells. The universal T cells may further contain a nucleic acid encoding a selection-suicide gene.
Owner:CITY OF HOPE
Chimeric receptors with 4-1BB stimulatory signaling domain
InactiveUS20050113564A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsNatural Killer Cell Inhibitory ReceptorsT cell
The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. Also included is a method for obtaining an enriched population of NK cells from a mixed population of NK cells and T cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Modified cell line and method for expansion of NK cell
ActiveUS7435596B2Highly efficient transductionBiocideGenetic material ingredientsCD137Natural Killer Cell Inhibitory Receptors
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
IL-2 selective agonists and antagonists
InactiveUS6955807B1Great therapeutic useToxic reductionBacteriaSugar derivativesNatural Killer Cell Inhibitory ReceptorsNucleotide
The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
Owner:AICURIS GMBH & CO KG
Compounds for targeted immunotherapy
Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC
IL-2 selective agonists and antagonists
The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
Owner:AICURIS GMBH & CO KG
Disease therapy with chimeric antigen receptor (CAR) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
InactiveUS20160361360A1Maintain self-toleranceModulate durationAntibacterial agentsPeptide/protein ingredientsAutoimmune conditionDebulking Procedure
The present invention concerns CAR, CAR-T and CAR-NK constructs, preferably comprising a scFv antibody fragment against a disease-associated antigen or a hapten. More preferably, the antigen is a TAA, such as Trop-2. The constructs may be administered to a subject with a disease, such as cancer, autoimmune disease, or immune dysfunction disease, to induce an immune response against disease-associated cells. Where the constructs bind to a hapten, the subject is first treated with a hapten-conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments, such as debulking procedures (e.g., surgery, chemotherapy, radiation therapy) or coadministration of other agents. More preferably, administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease-associated antigen. Most preferably, an antibody against CD74 or HLA-DR is administered to reduce systemic immunotoxicity induced by the constructs.
Owner:IMMUNOMEDICS INC
Expansion of NK cells and therapeutic uses thereof
ActiveUS20060093605A1Highly efficient transductionImmunoglobulin superfamilyGenetically modified cellsCD137Natural Killer Cell Inhibitory Receptors
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Human anti-KIR antibodies
ActiveUS8119775B2Antibacterial agentsSugar derivativesNatural Killer Cell Inhibitory ReceptorsMonoclonal antibody
Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
Owner:UNIV DEGLI STUDI DI GENOVA GENOVA IT +2
Therapeutic and Diagnostic Methods and Compositions Targeting 4Ig-B7-H3 and its Counterpart Nk Cell Receptor
ActiveUS20080081346A1Accurate detectionInhibition effectAntipyreticAntibody mimetics/scaffoldsNatural Killer Cell Inhibitory ReceptorsNK Cell Receptors
The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.
Owner:INNATE PHARMA SA +1
Method for amplifying NK cells of human beings under condition of in vitro culture
InactiveCN101684456AIncrease the amplification factorHigh purityBlood/immune system cellsForeign genetic material cellsPeripheral blood mononuclear cellNatural Killer Cell Inhibitory Receptors
The invention discloses a method for amplifying NK cells of human beings under the condition of in vitro culture, which is characterized in that a peripheral blood mononuclear cell (PBMC) is taken asthe original culturing material, and the PBMC is cultured together with an engineering cell which is built by adopting the genetic engineering method and is used for stimulating the growth of the NK cell. The built engineering cell which is used for stimulating the growth of the NK cell expresses several cytokines (IL-2, IL-12, IL-15, IL-18, 4-1BB) which can promote the growth of the NK cell on the surface of the K562 cell; after irradiation and inactivation with gamma-rays, the engineering cell is cultured with the PBMC in vitro, as a result, the amplification effect of the stimulation methodin the invention is hundreds of times stronger than that of the currently universal method in which soluble cytokines are added purely to the culture solution; and after cultured for 3 weeks, the non-NK cells in the PBMC are mainly dead and disappeared, the NK cells are proliferated in great quantity, the purity of the NK cells reaches over 96% and the total number of the NK cells is amplified byover 1500 times.
Owner:JIANGMEN LUOSEN BIO PHARMA
Combinatorial interleukin-2 muteins
InactiveUS20060160187A1Maintaining and enhancing proliferationLower Level RequirementsPeptide/protein ingredientsTissue cultureNatural Killer Cell Inhibitory ReceptorsInterleukin II
Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins have lower toxicity than native IL-2 or Proleukin® IL-2, while maintaining or enhancing NK cell-mediated effects, and can be used in pharmaceutical compositions for use in treatment of cancer, and in stimulating the immune response.
Owner:CHIRON CORP
Method for constructing human peripheral blood immune cell bank
ActiveCN102758259AHigh activityHigh purityMicroorganism librariesBlood/immune system cellsPeripheral blood mononuclear cellNatural Killer Cell Inhibitory Receptors
The invention discloses a method for constructing a human peripheral blood immune cell bank. The method comprises the following steps of: collecting human peripheral blood, separating autologous plasma, separating a peripheral blood mononuclear cell, separating a mononuclear cell by the peripheral blood mononuclear cell and freezing, separating a T lymphocyte by the peripheral blood mononuclear cell and freezing, separating a B lymphocyte by the peripheral blood mononuclear cell and freezing, separating an NK cell by the peripheral blood mononuclear cell and freezing, and encoding and puttingin storage. According to the invention, immune cells of health or young people are separated and are respectively independently frozen, and relative numbers are stored and put into storage, so that the stored human immune cells have the characteristics of high activity, high purity and convenience for use, and fetal calf serum can be replaced by the human autologous plasma, so that introduction of a foreign protein can be avoided. Meanwhile, the method, provided by the invention, has the advantages of low cost, low requirements on laboratory conditions, and wide application.
Owner:济南赛尔生物科技股份有限公司
Methods for Enhancing Natural Killer Cell Proliferation and Activity
InactiveUS20130011376A1Function increaseHigh cytotoxic activityOrganic active ingredientsBiocideNatural killer cellCytokine
Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and / or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof.
Owner:GAMIDA CELL
Method used for in vitro proliferation of NK cells
ActiveCN103756963AIncrease lethalityEasy to synthesizeBlood/immune system cellsSerum free mediaPeripheral blood mononuclear cell
Owner:SHANGHAI CLAISON BIOTECH
Methods and Compositions for Natural Killer Cells
ActiveUS20150190471A1Reduce in quantityIncrease the number ofPeptide/protein ingredientsCulture processNatural killer cellWilms' tumor
The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Non-lethal methods for conditioning a recipient for bone marrow transplantation
InactiveUS6217867B1Reduce proliferationDiminished cytotoxic activityBiocideOrganic active ingredientsGackstroemiaAcquired immunodeficiency
The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.
Owner:PITTSBURGH UNIV OF
Engineering and delivery of therapeutic compositions of freshly isolated cells
ActiveUS8450112B2Simple procedureGood treatment effectGenetic material ingredientsFermentationNatural Killer Cell Inhibitory ReceptorsCD8
The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and / or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and / or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.
Owner:MAXCYTE
Modified Natural Killer Cells and Uses Thereof
ActiveUS20170073638A1Polypeptide with localisation/targeting motifCell receptors/surface-antigens/surface-determinantsNatural Killer Cell Inhibitory ReceptorsNatural killer cell
The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and / or survival of NK cells.
Owner:NAT UNIV OF SINGAPORE +1
Monoclonal antibodies against nkg2a
ActiveUS20090208416A1Improve bioavailabilityImprove stabilitySenses disorderAntipyreticPresent methodDendritic cell
The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
Owner:UNIV DEGLI STUDI DI GENOVA GENOVA IT +1
Method for in-vitro amplification of NK cells
InactiveCN102994449AEasy to synthesizeIncrease lethalityBlood/immune system cellsSerum free mediaPeripheral blood mononuclear cell
The invention relates to a method for in-vitro amplification of NK cells, and in particular relates to a method for massive in-vitro amplification of NK cells, wherein the method comprises the following steps of: a, inoculating a peripheral blood mononuclear cell in a CD3McAb and CD226McAb pre-coated culture bottle for coculture; b, adding 1L-2 and 1L-18, coculturing for 72hours to stimulate amplification of NK cells; c, transferring the NK cells, K562 cells after lethal treatment and a serum-free medium containing 1L-2 and 1L-18 in a cell culture bag for coculture; and d, collecting the NK cells. According to the method for in-vitro amplification of the NK cells, two antibodies CD3McAb and CD226McAb are simultaneously coated, so the cell factor synthesis and ADCC effect are promoted, and killing toxicity of the NK cells is remarkably improved; the activation and amplification on the NK cells are achieved just by the 1L-2 and 1L-18 cell factors, so the amplification multiple and cell toxicity of the NK cells are guaranteed, and the cost of cell culture is reduced.
Owner:SHANGHAI CLAISON BIOTECH
Anti-zB7H6 antibody-drug conjugates
ActiveUS7858759B2Compound screeningApoptosis detectionNatural Killer Cell Inhibitory ReceptorsAntibody conjugate
Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
Owner:ZYMOGENETICS INC
Methods and compositions for modulating interleukin-21 receptor activity
InactiveUS7198789B2Enhance immune cell activityReduce Fc receptor bindingBiocidePeptide/protein ingredientsInfectious DisorderNatural Killer Cell Inhibitory Receptors
Methods and compositions for modulating interleukin-21 (IL-21) / IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21 / IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21 / IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
Owner:GENETICS INST INC
Rhodococcus ruber and application of same as immunologic adjuvant in preparing vaccine
ActiveCN109576180AWill not cause accidental infectionReduce pollutionBacteriaMicroorganism based processesSide effectShort terms
The invention discloses rhodococcus ruber and application of same as an immunologic adjuvant in preparing vaccine. The rhodococcus ruber is also called rhodococcus ruber RDC-01, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 16640. The rhodococcus ruber disclosed by the invention has the function of increasing and regulating the body immunity andis capable of nonspecifically enhancing the activity of TB (Tuberculosis) lymphocyte, macrophagocyte and NK cells and inducing multiple cell factors such as interferon, and the rhodococcus ruber canbe used as the immunologic adjuvant after being inactivated so as to be added in an oil-adjuvant inactive vaccine, so that generation of an animal antibody induced by the vaccine can be obviously promoted; compared with single use of the oil-adjuvant inactive vaccine, a high-titre antibody can be generated, the use is safe, long-term and short-term toxic and side effects are not generated, and anapplication prospect in the field of preparation of vaccines for animals is good.
Owner:北京利昂盛生物技术有限公司
Antibacterial and antitumor application of NK cell exosome and related miRNA
ActiveCN107998149AGood treatment effectLittle side effectsAntibacterial agentsOrganic active ingredientsBacteroidesAntibiosis
The invention discloses antibacterial and antitumor application of exosomes secreted by NK cells (aNK) activated by transmembrane IL-21 and multiple miRNAs contained in the exosomes, and provides a new method for bacterial infection and antitumor treatment. The method has the advantages that 1, the method is different from antibiotic treatment, and exosome antibiosis has lower side effects; 2, effects of antibacterial treatment can be enhanced through joint use; 3, the exosomes can be stored at low temperature, the miRNAs can be artificially synthesized, costs are low and large-scale production can be achieved; 4, the exosomes and the multiple miRNAs have inhibitory effects on a variety of bacteria, and have wider antibacterial spectra; 5, the miRNAs act on a variety of shared signal pathways of tumor cells, can inhibit a variety of tumors, and have a wide range of antitumor application.
Owner:ZHEJIANG UNIV +1
Method for amplification and activation of NK cells by K562 cells
ActiveCN103232973AHelp identify and killHelp activate recognition and killMammal material medical ingredientsBlood/immune system cellsNatural Killer Cell Inhibitory ReceptorsCD86
The invention discloses a method for amplification and activation of NK cells by K562 cells. The method comprises that through synergism of K562 cells transfected by transmembrane interleukin 21, CD14, CD19, CD86 and CD137, and low-concentration interleukin 2, NK cells are subjected to directed amplification and activation. Compared with the existing similar compounds, the compound provided by the invention has a stronger lymphocyte amplification and activation capability and higher efficiency. The method has wide prospects in immunological therapy.
Owner:杭州中赢生物医疗科技有限公司
Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
ActiveUS9067997B2Efficiently reduce or eliminate concanavalinReduce and eliminate KIR2DLBiocideAntipyreticDiseaseNatural Killer Cell Inhibitory Receptors
Owner:INNATE PHARMA SA
Compounds for targeted immunotherapy
Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC
Expansion method of various lymphocyte subpopulations and application of expansion method
ActiveCN105624107ASuppress deathImprove developmentGenetic material ingredientsMammal material medical ingredientsWhite blood cellNatural Killer Cell Inhibitory Receptors
The invention discloses an expansion method of various lymphocyte subpopulations and application of the expansion method to preparation of an adoptive immunotherapy medicine for cancers. The expansion method comprises the following steps: S1, adding IFN gamma and zoledronic acid into a culture medium of PBMC collected in the blood of a tumor patient, and re-adding an OKT3 antibody and recombinant human interleukin-2 after culture to stimulate PBMC so as to finish preliminary expansion; S2, after finish of preliminary expansion, mixing immune lymphocytes with feeder layer cells, and after adding zoledronic acid, an OKT3 antibody and recombinant human interleukin-2, continually performing expansion. By adoption of the expansion method, after twice expansion, the sum of the immune cells can be 10,000 to 80,000 times by expansion, the expanded immune cells include alpha beta T cells, gamma delta T cells, NKT cells and NK cells, and tumor cells can be directly killed, or a cellular immunotherapy drug is prepared to kill the tumor cells.
Owner:杭州朔溪生物医药有限公司
Methods and compositions for inducing hematopoietic cell differentiation
InactiveUS20180072992A1Improve efficiencyPromote differentiationCulture processCell culture mediaProgenitorHematopoietic cell
The invention provides culture platforms, cell media, and methods of differentiating pluriptent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of ER formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.
Owner:FATE THERAPEUTICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com